The use of “omics” to guide the selection of targeted therapy

Steven M. Kornblau

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

In this book, the role of many different proteins, pathways, or genetic events in affecting the function of leukemic cells, as well as their suitability for therapeutic modulation, is discussed. However, since acute myeloid leukemia (AML) is a very heterogeneous disease, it will be necessary to match the characteristics of individual patients to the selection of the right targeted agent in order to maximizen efficacy. In this chapter, we discuss how the application of the numerous molecular profiling arrays that are now available can be utilized to provide the answer to this dilemma. The development of methods to combine data from multiple arrays, termed “integromics” will enable a more sophisticated application of “omic” data that will facilitate the selection of combinations of targeted agents on an individualized basis.

Original languageEnglish
Title of host publicationTargeted Therapy of Acute Myeloid Leukemi
PublisherSpringer New York
Pages151-173
Number of pages23
ISBN (Electronic)9781493913930
ISBN (Print)9781493913923
DOIs
StatePublished - 1 Jan 2015
Externally publishedYes

Keywords

  • Gene Expression Profiling (Gep)
  • Integromics
  • Omics
  • Proteomics
  • Reverse Phase Protein Array (Rppa)
  • Single Nucleotide Polymorphism (Snp)
  • Whole Genome Sequencing

Fingerprint

Dive into the research topics of 'The use of “omics” to guide the selection of targeted therapy'. Together they form a unique fingerprint.

Cite this